Candesant Biomedical, a medical device company devoted to providing non-invasive treatments for hyperhidrosis, has unveiled the results of its groundbreaking clinical trial for its revolutionary sweat control patch. This three-minute patch has been proven to significantly reduce excessive underarm sweating in patients with primary axillary hyperhidrosis, providing a convenient and effective solution to this annoying and often embarrassing condition.
At the 2023 annual meeting of the American Academy of Dermatology, a groundbreaking trial, known as SAHARA, was presented with remarkable results. This randomized, double-blind, sham-controlled, multicenter trial demonstrated the effectiveness and safety of the sweat control patch. Participants reported no serious adverse events at any time, making it a successful and well-tolerated treatment.1
The recent SAHARA study results are a breakthrough for people suffering from hyperhidrosis – demonstrating statistically significant, clinically meaningful improvements in Hyperhidrosis Disease Severity Scale scores, sweat production and quality of life.
David Pariser, MD, FACP, FAAD – professor of the Eastern Virginia Medical School Department of Dermatology, cofounder of Virginia Clinical Research, Inc., past president of the American Academy of Dermatology, and founding member of the International Hyperhidrosis Society – commented on the potential of the sweat control patch to set a new standard of care for the treatment of primary axillary hyperhidrosis. If this patch is approved by the U.S. Food and Drug Administration, it could be a life-changing option for both providers and patients.
Niquette Hunt, Founder and CEO of Candesant, is ecstatic about the results of their SAHARA pivotal trial. If approved, their investigational patch could provide millions of people with much-needed relief from the physical, emotional, financial, and aesthetic effects of excessive underarm sweating. It’s a potential game-changer for those suffering from this condition.
Novel Mechanism of Action
The revolutionary and patented SweatTech™ technology is being reviewed by the U.S. Food and Drug Administration as a potential sweat control patch. When applied by a healthcare provider, the single-use disposable patch uses heat to precisely microtarget sweat glands, significantly reducing sweat production. This is the first clinical application to harness heat generated when sodium comes into contact with water in sweat, and the only patented medical device based on the scientific principle.
Around 15.3 million Americans suffer from the condition of hyperhidrosis, and experts believe that this number is a severe underestimation. In fact, the International Hyperhidrosis Society claims that one in three U.S. adults (85.2 million) experience bothersome excessive underarm sweating. A survey from the American Society for Dermatologic Surgery discovered that 58% of those seeking aesthetic treatments are most bothered by their excessive sweating.
About Candesant Biomedical
Candesant Biomedical is revolutionizing the medical device industry with their revolutionary SweatTech technology, the first non-invasive patch designed to provide relief to those suffering from excessive sweating, or hyperhidrosis.
From the primary axillary hyperhidrosis or excessive underarm sweating, to facial, palmar, and plantar hyperhidrosis, Candesant is researching and developing solutions to provide relief to those living with this condition.